Sanofi Pasteur and MSD end joint vaccines business in Europe
(Thomson Reuters ONE) -
Sanofi Pasteur and MSD end joint vaccines business in Europe
Paris, France - January 2, 2017 - Sanofi and its vaccines global business unit
Sanofi Pasteur confirmed today the end of their vaccine joint-venture with MSD
(known as Merck & Co. Inc., in the United States and Canada), Sanofi Pasteur MSD
(SPMSD). Sanofi Pasteur and MSD will separately pursue their own vaccine
strategies in Europe, integrating their respective European vaccines business
into their operations. The change in operations took effect January 1, 2017.
Since its announcement in March 2016, the project has been managed in an open
dialogue with the SPMSD employees, unions and relevant external stakeholders, in
compliance with the applicable rules and regulations. During the transitional
period following the announcement of the ending of the joint-venture, SPMSD and
Sanofi and Merck, its shareholders, have been focused on a smooth and orderly
transition while achieving their public healthcare goals and upholding their
commitments to their employees, customers and business partners.
Each company will be able to define its own vaccines strategy to benefit public
health and create value for patients, healthcare professionals, and payers. In
November 2015, as part of its strategic roadmap 2020, Sanofi announced that it
would reshape its portfolio, namely through sustained leadership in vaccines.
About Sanofi
Sanofi, a global healthcare leader, discovers, develops and distributes
therapeutic solutions focused on patients' needs. Sanofi is organized into five
global business units: Diabetes and Cardiovascular, General Medicines and
Emerging Markets, Sanofi Genzyme, Sanofi Pasteur and Consumer Healthcare. Sanofi
is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).
Sanofi Pasteur, the vaccines division of Sanofi, provides more than 1 billion
doses of vaccine each year, making it possible to immunize more than 500 million
people across the globe. A world leader in the vaccine industry, Sanofi Pasteur
produces a portfolio of high quality vaccines that matches its areas of
expertise and meets public-health demand. The company's heritage, to create
vaccines that protect life, dates back more than a century. Sanofi Pasteur is
the largest company entirely dedicated to vaccines. Every day, the company
invests more than EUR 1 million in research and development. For more
information, please visit: www.sanofipasteur.com or www.sanofipasteur.us
Forward Looking Statements of Sanofi
This press release contains forward-looking statements as defined in the Private
Securities Litigation Reform Act of 1995, as amended. Forward-looking statements
are statements that are not historical facts. These statements include
projections and estimates and their underlying assumptions, statements regarding
plans, objectives, intentions and expectations with respect to future financial
results, events, operations, services, product development and potential, and
statements regarding future performance. Forward-looking statements are
generally identified by the words "expects", "anticipates", "believes",
"intends", "estimates", "plans" and similar expressions. Although Sanofi's
management believes that the expectations reflected in such forward-looking
statements are reasonable, investors are cautioned that forward-looking
information and statements are subject to various risks and uncertainties, many
of which are difficult to predict and generally beyond the control of Sanofi,
that could cause actual results and developments to differ materially from those
expressed in, or implied or projected by, the forward-looking information and
statements. These risks and uncertainties include among other things, the
uncertainties inherent in research and development, future clinical data and
analysis, including post marketing, decisions by regulatory authorities, such as
the FDA or the EMA, regarding whether and when to approve any drug, device or
biological application that may be filed for any such product candidates as well
as their decisions regarding labelling and other matters that could affect the
availability or commercial potential of such product candidates, the absence of
guarantee that the product candidates if approved will be commercially
successful, the future approval and commercial success of therapeutic
alternatives, the Group's ability to benefit from external growth opportunities,
trends in exchange rates and prevailing interest rates, the impact of cost
containment initiatives and subsequent changes thereto, the average number of
shares outstanding as well as those discussed or identified in the public
filings with the SEC and the AMF made by Sanofi, including those listed under
"Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements"
in Sanofi's annual report on Form 20-F for the year ended December 31, 2015.
Other than as required by applicable law, Sanofi does not undertake any
obligation to update or revise any forward-looking information or statements.
--------------------------------------------------------------------------------
Contacts:
Media Relations Investor Relations
Laurence Bollack George Grofik
Tel. : +33 (0)1 53 77 46 46 Tel.: +33 (0)1 53 77 45 45
mr(at)sanofi.com ir(at)sanofi.com
Press release (PDF):
http://hugin.info/152918/R/2068249/776661.pdf
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Sanofi via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 02.01.2017 - 08:00 Uhr
Sprache: Deutsch
News-ID 515390
Anzahl Zeichen: 6447
contact information:
Town:
PARIS
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 229 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Sanofi Pasteur and MSD end joint vaccines business in Europe"
steht unter der journalistisch-redaktionellen Verantwortung von
Sanofi (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
